Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00186563 · ClinicalTrials.gov registry record · NA
A Human In-vivo Model for the Detection of Inflammatory and Nociceptive Biomarkers
A NA study, sponsored by Martin Angst.
- Completed
- Registry status
- NA
- Development phase
- 13
- Enrollment target
NCT00186563: Completed NA study, sponsored by Martin Angst.
NCT00186563 is a NA study that has completed, run by Martin Angst. The registered enrollment target is 13 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00186563, a NA study, has completed, sponsored by Martin Angst.
- COMPLETED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
Study Summary
This study aims to establish a novel approach assisting the rational development of analgesic and anti-inflammatory drugs. In a first step we will test in healthy human volunteers whether proteins mediating inflammation and pain can be detected in an experimentally induced inflammatory skin lesion. Fluids that will be used to detect such proteins will be collected from the inflamed skin site via small porous catheters. We wish to establish the expression pattern of different proteins and correlate it with various tests assessing pain.
Interventions
- PROCEDURE Micro-plasmapheresis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Phase | NA |
What the finished NCT00186563 record still lists
NCT00186563 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Micro-plasmapheresis is the first listed.
NCT00186563 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00186563 about?
NCT00186563 is a clinical study titled "A Human In-vivo Model for the Detection of Inflammatory and Nociceptive Biomarkers". This study aims to establish a novel approach assisting the rational development of analgesic and anti-inflammatory drugs. In a first step we will test in healthy human volunteers whether proteins mediating inflammation and pain can be detected in an experimentally induced inflammatory skin lesion. ...
What is the current status of trial NCT00186563?
This trial is currently completed. It is a NA study. The enrollment target is 13 participants.
What interventions are being tested in trial NCT00186563?
The interventions under investigation include: Micro-plasmapheresis (PROCEDURE).
Who is sponsoring clinical trial NCT00186563?
This trial is sponsored by Martin Angst, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00186563's enrollment target sits among peer trials
13 1911th of 2000 higher than 88 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer